LON:FARN Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free FARN Stock Alerts GBX 120 0.00 (0.00%) (As of 04:44 AM ET) Add Compare Share Share Today's Range 117.55▼ 12050-Day Range 117.50▼ 27552-Week Range 113▼ 370Volume8,593 shsAverage Volume25,392 shsMarket Capitalization£82.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Faron Pharmaceuticals Oy alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Faron Pharmaceuticals Oy Stock (LON:FARN)Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.Read More FARN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FARN Stock News HeadlinesApril 16, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Faron Confirms Plans for the Coming Months Under New LeadershipApril 16, 2024 | finance.yahoo.comFaron Confirms Plans for the Coming Months Under New LeadershipApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 18, 2024 | finance.yahoo.comInside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AMLMarch 18, 2024 | finance.yahoo.comFaron Pharmaceuticals reports promising phase 1 results from BEXMAB studyMarch 14, 2024 | finance.yahoo.comFaron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of BexmarilimabMarch 13, 2024 | finance.yahoo.comFaron’s Financial Statement Release January 1 to December 31, 2023March 4, 2024 | uk.investing.comFaron Pharma secures €3.2 million convertible loanApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 19, 2024 | finanznachrichten.deNasdaq Helsinki Ltd: THE SHARES OF FARON PHARMACEUTICALS LTD. GIVEN OBSERVATION STATUSFebruary 1, 2024 | uk.investing.comFaron Pharmaceuticals Oy (FARN)January 25, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 25, 2024 | finance.yahoo.comDetailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS PopulationJanuary 23, 2024 | finance.yahoo.comFaron Pharmaceuticals Oy (FARN.L)January 11, 2024 | finanznachrichten.deFaron Pharmaceuticals Oy: Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB TrialJanuary 3, 2024 | finance.yahoo.comFaron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 11, 2023 | finance.yahoo.comFaron Pharmaceuticals presents "very positive" Phase 1 data at ASH ConferenceDecember 11, 2023 | lse.co.ukFaron Pharmaceuticals hails positive results of cancer drug trialDecember 11, 2023 | finance.yahoo.comInside information: Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial at the 65th American Society of Hematology (ASH) Annual MeetingDecember 7, 2023 | finance.yahoo.comFaron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports MedicineNovember 24, 2023 | morningstar.comFaron Pharmaceuticals Oy FARNNovember 6, 2023 | finance.yahoo.comFaron Pharmaceuticals initiates second phase of BEXMAB studyNovember 6, 2023 | finance.yahoo.comFaron Pharmaceuticals Oy's (LON:FARN) last week's 11% decline must have disappointed individual investors who have a significant stakeNovember 2, 2023 | finance.yahoo.comFaron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual MeetingOctober 27, 2023 | proactiveinvestors.comFaron Pharma raises €7.1m as cancer study continues apaceOctober 27, 2023 | finance.yahoo.comInside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade RegisterOctober 16, 2023 | proactiveinvestors.comFaron Pharmaceuticals' chief speaks after latest promising BEXMAB trial dataSee More Headlines Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FARN CUSIPN/A CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-30,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-166.16% Debt Debt-to-Equity Ratio121.51 Current Ratio0.59 Quick Ratio1.09 Sales & Book Value Annual Sales£-725,000.00 Price / Sales-113.89 Cash FlowGBX 6 per share Price / Cash Flow20.00 Book ValueGBX (22) per share Price / Book-5.45Miscellaneous Outstanding Shares68,810,000Free FloatN/AMarket Cap£82.57 million OptionableNot Optionable Beta-0.14 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Juho Markku Jalkanen M.D. (Age 46)MSc, Ph.D., Chief Operating Officer Comp: $544.28kDr. Markku Tapani Jalkanen Ph.D. (Age 70)Founder, CEO & Executive Director Comp: $241.01kMr. James M. O'Brien CPAM.B.A., Chief Financial OfficerDr. Maija Hollmen Ph.D.Chief Scientific OfficerMr. Vesa Karvonen L.L.M. (Age 52)General Counsel Ms. Jennifer Smith-ParkerHead of CommunicationsDr. Juhana HeinonenChief Commercial OfficerDr. Birge Berns M.D.Interim Chief Medical OfficerMore ExecutivesKey CompetitorsScancellLON:SCLPMereo BioPharma Group plc (MPH.L)LON:MPHFutura MedicalLON:FUMOpen OrphanLON:ORPHVerseonLON:VSNView All CompetitorsInsidersJohn PoulosSold 5,000 sharesTotal: £1.92 M ($383.00/share)John PoulosSold 5,000 sharesTotal: £1.86 M ($372.00/share) FARN Stock Analysis - Frequently Asked Questions How have FARN shares performed in 2024? Faron Pharmaceuticals Oy's stock was trading at GBX 305 on January 1st, 2024. Since then, FARN stock has decreased by 60.7% and is now trading at GBX 120. View the best growth stocks for 2024 here. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Acura Pharmaceuticals (ACUR), Carnival Co. & (CCL), Alphabet (GOOG), Hurricane Energy (HUR), International Consolidated Airlines Group (IAG), Northwest Pipe (NWPX), Petropavlovsk (POG) and TriQuint Semiconductor (TQNT). How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:FARN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
